South Korea · Delayed Price · Currency is KRW HYUNDAI BIOLAND Statistics
Total Valuation
HYUNDAI BIOLAND has a market cap or net worth of KRW 112.95 billion. The enterprise value is 102.16 billion.
| Market Cap | 112.95B |
| Enterprise Value | 102.16B |
Important Dates
The next estimated earnings date is Friday, July 31, 2026.
| Earnings Date | Jul 31, 2026 |
| Ex-Dividend Date | Apr 2, 2026 |
Share Statistics
HYUNDAI BIOLAND has 30.00 million shares outstanding. The number of shares has increased by 0.03% in one year.
| Current Share Class | 30.00M |
| Shares Outstanding | 30.00M |
| Shares Change (YoY) | +0.03% |
| Shares Change (QoQ) | -0.18% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.86% |
| Float | 19.50M |
Valuation Ratios
The trailing PE ratio is 9.05.
| PE Ratio | 9.05 |
| Forward PE | n/a |
| PS Ratio | 0.84 |
| PB Ratio | 0.81 |
| P/TBV Ratio | 0.83 |
| P/FCF Ratio | 7.27 |
| P/OCF Ratio | 6.09 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.78, with an EV/FCF ratio of 6.57.
| EV / Earnings | 8.19 |
| EV / Sales | 0.76 |
| EV / EBITDA | 5.78 |
| EV / EBIT | 7.90 |
| EV / FCF | 6.57 |
Financial Position
The company has a current ratio of 4.49, with a Debt / Equity ratio of 0.05.
| Current Ratio | 4.49 |
| Quick Ratio | 2.02 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.37 |
| Debt / FCF | 0.42 |
| Interest Coverage | 32.61 |
Financial Efficiency
Return on equity (ROE) is 9.32% and return on invested capital (ROIC) is 10.20%.
| Return on Equity (ROE) | 9.32% |
| Return on Assets (ROA) | 5.05% |
| Return on Invested Capital (ROIC) | 10.20% |
| Return on Capital Employed (ROCE) | 9.11% |
| Weighted Average Cost of Capital (WACC) | 8.79% |
| Revenue Per Employee | 396.01M |
| Profits Per Employee | 36.60M |
| Employee Count | 341 |
| Asset Turnover | 0.84 |
| Inventory Turnover | 1.62 |
Taxes
In the past 12 months, HYUNDAI BIOLAND has paid 80.55 million in taxes.
| Income Tax | 80.55M |
| Effective Tax Rate | 0.64% |
Stock Price Statistics
The stock price has decreased by -16.03% in the last 52 weeks. The beta is 0.85, so HYUNDAI BIOLAND's price volatility has been lower than the market average.
| Beta (5Y) | 0.85 |
| 52-Week Price Change | -16.03% |
| 50-Day Moving Average | 4,201.70 |
| 200-Day Moving Average | 4,387.00 |
| Relative Strength Index (RSI) | 36.82 |
| Average Volume (20 Days) | 103,006 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HYUNDAI BIOLAND had revenue of KRW 135.04 billion and earned 12.48 billion in profits. Earnings per share was 416.13.
| Revenue | 135.04B |
| Gross Profit | 54.57B |
| Operating Income | 12.94B |
| Pretax Income | 12.56B |
| Net Income | 12.48B |
| EBITDA | 17.68B |
| EBIT | 12.94B |
| Earnings Per Share (EPS) | 416.13 |
Balance Sheet
The company has 17.26 billion in cash and 6.47 billion in debt, with a net cash position of 10.79 billion or 359.70 per share.
| Cash & Cash Equivalents | 17.26B |
| Total Debt | 6.47B |
| Net Cash | 10.79B |
| Net Cash Per Share | 359.70 |
| Equity (Book Value) | 139.64B |
| Book Value Per Share | 4,662.98 |
| Working Capital | 67.98B |
Cash Flow
In the last 12 months, operating cash flow was 18.53 billion and capital expenditures -2.99 billion, giving a free cash flow of 15.54 billion.
| Operating Cash Flow | 18.53B |
| Capital Expenditures | -2.99B |
| Depreciation & Amortization | 4.74B |
| Net Borrowing | -8.44B |
| Free Cash Flow | 15.54B |
| FCF Per Share | 518.13 |
Margins
Gross margin is 40.41%, with operating and profit margins of 9.58% and 9.24%.
| Gross Margin | 40.41% |
| Operating Margin | 9.58% |
| Pretax Margin | 9.30% |
| Profit Margin | 9.24% |
| EBITDA Margin | 13.09% |
| EBIT Margin | 9.58% |
| FCF Margin | 11.51% |
Dividends & Yields
This stock pays an annual dividend of 35.00, which amounts to a dividend yield of 0.89%.
| Dividend Per Share | 35.00 |
| Dividend Yield | 0.89% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 16.83% |
| Buyback Yield | -0.03% |
| Shareholder Yield | 0.86% |
| Earnings Yield | 11.05% |
| FCF Yield | 13.76% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 17, 2024. It was a forward split with a ratio of 2.
| Last Split Date | May 17, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
HYUNDAI BIOLAND has an Altman Z-Score of 6.31 and a Piotroski F-Score of 6.
| Altman Z-Score | 6.31 |
| Piotroski F-Score | 6 |